Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
August 16 2022 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2022
Commission File Number: 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
CONTENTS
On August 16, 2022, Evogene Ltd. (“Evogene”) announced that its subsidiary, Lavie Bio Ltd., and ICL Group Ltd. (NYSE, TASE: ICL) entered into a strategic collaboration to
develop novel bio-stimulant products. As part of the collaboration, a subsidiary of ICL will invest $10 million in Lavie Bio. A copy of the press release is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this
“Form 6-K”) and is incorporated herein by reference.
The first second, third and fourth paragraphs and the section entitled “Forward-Looking Statements” of Exhibit 99.1 to this Form 6-K are incorporated by reference into the
registration statements on
Form F-3 (File No.
333-253300) and on Form S-8 (File Nos.
333-193788,
333-201443,
333-203856 and
333-259215)
of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: August 16, 2022
|
|
EVOGENE LTD.
(Registrant)
By: /s/ Yaron Eldad
Yaron Eldad
Chief Financial Officer
|
EXHIBIT INDEX
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Apr 2024 to May 2024
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From May 2023 to May 2024